Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: A report of the Late Effects Surveillance System (LESS)

M. Paulides, A. Kremers, W. Stöhr, S. Bielack, H. Jürgens, J. Treuner, J. D. Beck, T. Langer*

*Korrespondierende/r Autor/-in für diese Arbeit
53 Zitate (Scopus)

Abstract

Background. Prospective, longitudinal examinations of anthracycline-induced cardiomyopathy in a homogeneous cohort are rare in pediatric oncology. We herein report the results of observations on the frequency of cardiomyopathy in doxorubicin-treated sarcoma patients in Germany, Austria, and Switzerland. Procedure. The Late Effects Surveillance System (LESS) prospectively collects longitudinal data on late sequelae of antineoplastic therapy in Ewing-, soft tissue-, and osteosarcoma patients treated within the therapy trial protocols of the German Society of Pediatric Oncology and Hematology. Two hundred sixty-five relapse-free patients who had received doxorubicin for the treatment within the EICESS-92/EURO-E.W.I.N.G.-99, COSS-96, and CWS-96 therapy trials were serially examined by echocardiography. The analyzed population consisted of 142 males and 123 females. Their mean age at the end of therapy was 13 ± 5 years. The mean follow-up time was 34 ± 12 months. The mean cumulative doxorubicin dose was 290 ± 91 mg/m2. Results. In this cohort, the total cumulative incidence of doxorubicin-induced cardiomyopathy was 7.5%. Four patients (1.5%) suffered from a symptomatic cardiomyopathy and 16 (6%) from a subclinical cardiomyopathy. Cardiomyopathy manifested in 11 cases already under antineoplastic therapy and in the remaining nine cases at a median of 26 days (range: 17-174 days) after stopping antineoplastic therapy. Univariate and multivariable analysis did not confirm any of the known risk factors for developing anthracycline-induced cardiomyopathy in our patient group within the described time interval. Conclusions. After a mean follow-up of 34 ± 12 months, cumulative incidence of doxorubicin-induced cardiomyopathy in our pediatric sarcoma patients was at the lower end of that reported by other groups.

OriginalspracheEnglisch
ZeitschriftPediatric Blood and Cancer
Jahrgang46
Ausgabenummer4
Seiten (von - bis)489-495
Seitenumfang7
ISSN1545-5009
DOIs
PublikationsstatusVeröffentlicht - 04.2006

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: A report of the Late Effects Surveillance System (LESS)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren